

Klaus Jung

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2297338/klaus-jung-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

444 papers	15,138 citations	66 h-index	101 g-index
479 ext. papers	16,596 ext. citations	4.9 avg, IF	6.15 L-index

#	Paper	IF	Citations
444	The discriminative ability of Prostate Health Index to detect prostate cancer is enhanced in combination with miR-222-3p. <i>Cancer Biomarkers</i> , 2021 , 30, 381-393	3.8	1
443	PHI density prospectively improves prostate cancer detection. <i>World Journal of Urology</i> , 2021 , 39, 3273-3279	3.7	5
442	Comparison of PHI and PHI Density for Prostate Cancer Detection in a Large Retrospective Caucasian Cohort. <i>Urologia Internationalis</i> , 2021 , 1-6	1.9	2
441	Inhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients. <i>Nature Communications</i> , 2020 , 11, 929	17.4	46
440	Limited utility of qPCR-based detection of tumor-specific circulating mRNAs in whole blood from clear cell renal cell carcinoma patients. <i>BMC Urology</i> , 2020 , 20, 7	2.2	2
439	Decreased Mitochondrial DNA Content Drives OXPHOS Dysregulation in Chromophobe Renal Cell Carcinoma. <i>Cancer Research</i> , 2020 , 80, 3830-3840	10.1	2
438	Circular RNAs and Their Linear Transcripts as Diagnostic and Prognostic Tissue Biomarkers in Prostate Cancer after Prostatectomy in Combination with Clinicopathological Factors. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	3
437	Endocytosis-Mediated Replenishment of Amino Acids Favors Cancer Cell Proliferation and Survival in Chromophobe Renal Cell Carcinoma. <i>Cancer Research</i> , 2020 , 80, 5491-5501	10.1	1
436	Instability of circular RNAs in clinical tissue samples impairs their reliable expression analysis using RT-qPCR: from the myth of their advantage as biomarkers to reality. <i>Theranostics</i> , 2020 , 10, 9268-9279	12.1	8
435	Papillary Renal Cell Carcinomas Rewire Glutathione Metabolism and Are Deficient in Both Anabolic Glucose Synthesis and Oxidative Phosphorylation. <i>Cancers</i> , 2019 , 11,	6.6	6
434	Circular RNAs in Clear Cell Renal Cell Carcinoma: Their Microarray-Based Identification, Analytical Validation, and Potential Use in a Clinico-Genomic Model to Improve Prognostic Accuracy. <i>Cancers</i> , 2019 , 11,	6.6	26
433	Lymphatic micrometastases predict biochemical recurrence in patients undergoing radical prostatectomy and pelvic lymph node dissection for prostate cancer. <i>Aktuelle Urologie</i> , 2019 , 50, 612-618	8.4	1
432	A Novel Predictor Tool of Biochemical Recurrence after Radical Prostatectomy Based on a Five-MicroRNA Tissue Signature. <i>Cancers</i> , 2019 , 11,	6.6	13
431	Apelin and apelin receptor expression in renal cell carcinoma. <i>British Journal of Cancer</i> , 2019 , 120, 633-639	13.7	14
430	Plasma miR-15b-5p and miR-590-5p for distinguishing patients with bladder cancer from healthy individuals. <i>Oncology Reports</i> , 2019 , 42, 1609-1620	3.5	6
429	Karyopherin Alpha 2 Is an Adverse Prognostic Factor in Clear-Cell and Papillary Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e167-e175	3.3	7
428	Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role. <i>Journal of Urology</i> , 2018 , 199, 370-377	2.5	40

427	Diagnostic and Prognostic Potential of MicroRNA Maturation Regulators Drosha, AGO1 and AGO2 in Urothelial Carcinomas of the Bladder. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	5
426	Circulating miRNAs in blood and urine as diagnostic and prognostic biomarkers for bladder cancer: an update in 2017. <i>Biomarkers in Medicine</i> , 2018 , 12, 667-676	2.3	18
425	The value of digital rectal examination in clinical practice. <i>AME Medical Journal</i> , 2018 , 3, 45-45	1	0
424	miR-9-5p in Nephrectomy Specimens is a Potential Predictor of Primary Resistance to First-Line Treatment with Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2018 , 10,	6.6	10
423	Circular RNAs: a new class of biomarkers as a rising interest in laboratory medicine. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018 , 56, 1992-2003	5.9	16
422	Antioxidant and antiproliferative potentials of methanol extract of <i>Xylopia aethiopica</i> (Dunal) A. Rich in PC-3 and LNCaP cells. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2017 , 28, 403-412	1.6	6
421	Re: Serum Vitamin D is Not Helpful for Predicting Prostate Cancer Aggressiveness Compared with the Prostate Health Index: C. Stephan, M. Lein, J. Matalon, E. Kilic, Z. Zhao, J. Busch and K. Jung J Urol 2016;196:709-714. <i>Journal of Urology</i> , 2017 , 197, 822-823	2.5	
420	Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	22
419	miR-199a-3p and miR-214-3p improve the overall survival prediction of muscle-invasive bladder cancer patients after radical cystectomy. <i>Cancer Medicine</i> , 2017 , 6, 2252-2262	4.8	25
418	Punicalagin, a polyphenol from pomegranate fruit, induces growth inhibition and apoptosis in human PC-3 and LNCaP cells. <i>Chemico-Biological Interactions</i> , 2017 , 274, 100-106	5	33
417	Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	7
416	Does the Prostate Health Index Depend on Tumor Volume?-A Study on 196 Patients after Radical Prostatectomy. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	13
415	Adipophilin as prognostic biomarker in clear cell renal cell carcinoma. <i>Oncotarget</i> , 2017 , 8, 28672-28682	3.3	13
414	The prostate health index PHI predicts oncological outcome and biochemical recurrence after radical prostatectomy - analysis in 437 patients. <i>Oncotarget</i> , 2017 , 8, 79279-79288	3.3	14
413	Loss of cadherin related family member 5 (CDHR5) expression in clear cell renal cell carcinoma is a prognostic marker of disease progression. <i>Oncotarget</i> , 2017 , 8, 75076-75086	3.3	6
412	Renal oncocytoma characterized by the defective complex I of the respiratory chain boosts the synthesis of the ROS scavenger glutathione. <i>Oncotarget</i> , 2017 , 8, 105882-105904	3.3	16
411	Synthesis, Antiproliferative, and Antiangiogenic Activities of Benzochromene and Benzoquinoline Derivatives on Prostate Cancer in vitro. <i>Letters in Drug Design and Discovery</i> , 2017 , 14, 398-413	0.8	2
410	The translational potential of microRNAs as biofluid markers of urological tumours. <i>Nature Reviews Urology</i> , 2016 , 13, 734-752	5.5	81

409	Serum Vitamin D is Not Helpful for Predicting Prostate Cancer Aggressiveness Compared with the Prostate Health Index. <i>Journal of Urology</i> , 2016 , 196, 709-14	2.5	6
408	New Insights Into the Mechanism of COP9 Signalosome-Cullin-RING Ubiquitin-Ligase Pathway Deregulation in Urological Cancers. <i>International Review of Cell and Molecular Biology</i> , 2016 , 323, 181-229	6	5
407	TRPM4 protein expression in prostate cancer: a novel tissue biomarker associated with risk of biochemical recurrence following radical prostatectomy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016 , 468, 345-55	5.1	29
406	Diagnostic and prognostic potential of circulating cell-free genomic and mitochondrial DNA fragments in clear cell renal cell carcinoma patients. <i>Clinica Chimica Acta</i> , 2016 , 452, 109-19	6.2	43
405	The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 1969-77	12.9	128
404	Integrated microRNA and mRNA Signature Associated with the Transition from the Locally Confined to the Metastasized Clear Cell Renal Cell Carcinoma Exemplified by miR-146-5p. <i>PLoS ONE</i> , 2016 , 11, e0148746	3.7	62
403	Cooperative Effect of miR-141-3p and miR-145-5p in the Regulation of Targets in Clear Cell Renal Cell Carcinoma. <i>PLoS ONE</i> , 2016 , 11, e0157801	3.7	44
402	BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients. <i>Oncotarget</i> , 2016 , 7, 6015-28	3.3	6
401	Integration of tissue metabolomics, transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate cancer. <i>Oncotarget</i> , 2016 , 7, 1421-38	3.3	48
400	Epithelial-mesenchymal transition-associated microRNA/mRNA signature is linked to metastasis and prognosis in clear-cell renal cell carcinoma. <i>Scientific Reports</i> , 2016 , 6, 31852	4.9	33
399	The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged 65 years. <i>BJU International</i> , 2016 , 117, 72-9	5.6	51
398	Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015 , 53, 1109-18	5.9	22
397	Antioxidant, antiangiogenic and antiproliferative activities of root methanol extract of <i>Calliandra portoricensis</i> in human prostate cancer cells. <i>Journal of Integrative Medicine</i> , 2015 , 13, 185-93	4	22
396	Synthesis, crystal structure and effect of indeno[1,2-b]indole derivatives on prostate cancer in vitro. Potential effect against MMP-9. <i>European Journal of Medicinal Chemistry</i> , 2015 , 96, 281-95	6.8	23
395	Re: Scott A. Tomlins, John R. Day, Robert J. Lonigro, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. <i>Eur Urol</i> . In press. http://dx.doi.org/10.1016/j.eururo.2015.04.039 . <i>European Urology</i> , 2015 , 68, e106-7	10.2	4
394	Piwi-interacting RNAs as novel prognostic markers in clear cell renal cell carcinomas. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015 , 34, 61	12.8	70
393	Current biomarkers for diagnosing of prostate cancer. <i>Future Oncology</i> , 2015 , 11, 2743-55	3.6	9
392	miRNAs dysregulated in association with Gleason grade regulate extracellular matrix, cytoskeleton and androgen receptor pathways. <i>Journal of Pathology</i> , 2015 , 237, 226-37	9.4	25

391	Urinary thiosulfate as failed prostate cancer biomarker - an exemplary multicenter re-evaluation study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015 , 53, 477-83	5.9	3
390	Prognostic relevance of proliferation markers (Ki-67, PHH3) within the cross-relation of ERG translocation and androgen receptor expression in prostate cancer. <i>Pathology</i> , 2015 , 47, 629-36	1.6	15
389	Glutathione S-transferase-pi protein expression in prostate cancer--not always a useful diagnostic tool. <i>Histopathology</i> , 2015 , 67, 577-9	7.3	3
388	Nucleic acid-based tissue biomarkers of urologic malignancies. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2014 , 51, 173-99	9.4	28
387	Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers of bone metastasis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014 , 1846, 425-38	11.2	29
386	KDM5C is overexpressed in prostate cancer and is a prognostic marker for prostate-specific antigen-relapse following radical prostatectomy. <i>American Journal of Pathology</i> , 2014 , 184, 2430-7	5.8	48
385	Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2014 , 51, 200-31	9.4	57
384	Serum testosterone improves the accuracy of Prostate Health Index for the detection of prostate cancer. <i>Clinical Biochemistry</i> , 2014 , 47, 916-20	3.5	2
383	Prostate-specific antigen and other serum and urine markers in prostate cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014 , 1846, 99-112	11.2	40
382	miRNA panels as biomarkers for bladder cancer. <i>Biomarkers in Medicine</i> , 2014 , 8, 733-46	2.3	17
381	Myoglobin expression in prostate cancer is correlated to androgen receptor expression and markers of tumor hypoxia. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014 , 465, 419-27	5.1	15
380	Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa). <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2014 , 25, 55-78	2.4	11
379	Risk prediction models for biochemical recurrence after radical prostatectomy using prostate-specific antigen and Gleason score. <i>Asian Journal of Andrology</i> , 2014 , 16, 897-901	2.8	7
378	Biomarker des Knochenstoffwechsels in Serum und Urin bei ossilen Metastasen 2014 , 49-68		
377	miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. <i>Journal of Molecular Diagnostics</i> , 2013 , 15, 695-705	5.1	115
376	Tissue metabolite profiling identifies differentiating and prognostic biomarkers for prostate carcinoma. <i>International Journal of Cancer</i> , 2013 , 133, 2914-24	7.5	38
375	MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer. <i>Clinical Chemistry</i> , 2013 , 59, 1595-603	5.5	46
374	Renal cell neoplasias: reversion-inducing cysteine-rich protein with Kazal motifs discriminates tumor subtypes, while extracellular matrix metalloproteinase inducer indicates prognosis. <i>Journal of Translational Medicine</i> , 2013 , 11, 258	8.5	6

373	Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy. <i>Clinica Chimica Acta</i> , 2013 , 416, 5-10	6.2	55
372	Pitfalls in the determination of circulating matrix metalloproteinases and their inhibitors by disregarding fundamental laboratory principles. <i>American Heart Journal</i> , 2013 , 165, e31	4.9	
371	Deregulation of the COP9 signalosome-cullin-RING ubiquitin-ligase pathway: mechanisms and roles in urological cancers. <i>International Journal of Biochemistry and Cell Biology</i> , 2013 , 45, 1327-37	5.6	12
370	N'-Formyl-2-(5-nitrothiophen-2-yl)benzothiazole-6-carbohydrazide as a potential anti-tumour agent for prostate cancer in experimental studies. <i>Journal of Pharmacy and Pharmacology</i> , 2013 , 65, 411-22	4.8	9
369	Artificial neural networks and prostate cancer--tools for diagnosis and management. <i>Nature Reviews Urology</i> , 2013 , 10, 174-82	5.5	46
368	Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]prostate-specific antigen-based prostate health index for detection of prostate cancer. <i>Clinical Chemistry</i> , 2013 , 59, 280-8	5.5	84
367	Multicenter evaluation of [-2]prostate-specific antigen and the prostate health index for detecting prostate cancer. <i>Clinical Chemistry</i> , 2013 , 59, 306-14	5.5	102
366	Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course. <i>International Journal of Cancer</i> , 2013 , 132, 807-12	5.5	26
365	Comparison of p40 (p63) and p63 expression in prostate tissues--which one is the superior diagnostic marker for basal cells?. <i>Histopathology</i> , 2013 , 63, 50-6	7.3	20
364	Identification of microRNAs in blood and urine as tumour markers for the detection of urinary bladder cancer. <i>Oncology Reports</i> , 2013 , 30, 1949-56	3.5	65
363	A new algorithm for integrated analysis of miRNA-mRNA interactions based on individual classification reveals insights into bladder cancer. <i>PLoS ONE</i> , 2013 , 8, e64543	3.7	25
362	The antiapoptotic function of miR-96 in prostate cancer by inhibition of FOXO1. <i>PLoS ONE</i> , 2013 , 8, e80807	3.7	60
361	MicroRNAs as new diagnostic and prognostic biomarkers in urological tumors. <i>Critical Reviews in Oncogenesis</i> , 2013 , 18, 289-302	1.3	18
360	The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer. <i>Biological Chemistry</i> , 2012 , 393, 379-89	4.5	28
359	Feedback networks between microRNAs and epigenetic modifications in urological tumors. <i>Epigenetics</i> , 2012 , 7, 315-25	5.7	28
358	Value of prostate specific antigen density and percent free prostate specific antigen for prostate cancer prognosis. <i>Journal of Urology</i> , 2012 , 188, 2165-70	2.5	7
357	MiR-133b targets antiapoptotic genes and enhances death receptor-induced apoptosis. <i>PLoS ONE</i> , 2012 , 7, e35345	3.7	74
356	Selenoprotein P status correlates to cancer-specific mortality in renal cancer patients. <i>PLoS ONE</i> , 2012 , 7, e46644	3.7	38

355	RECK overexpression decreases invasive potential in prostate cancer cells. <i>Prostate</i> , 2012 , 72, 948-54	4.2	20
354	Effect of quinolinyl acrylate derivatives on prostate cancer in vitro and in vivo. <i>Investigational New Drugs</i> , 2012 , 30, 1426-33	4.3	14
353	Expression of endothelial factors in prostate cancer: a possible role of caveolin-1 for tumour progression. <i>Oncology Reports</i> , 2012 , 27, 389-95	3.5	16
352	Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomas. <i>International Journal of Biological Sciences</i> , 2012 , 8, 1363-74	11.2	75
351	Reference miRNAs for miRNAome analysis of urothelial carcinomas. <i>PLoS ONE</i> , 2012 , 7, e39309	3.7	65
350	Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. <i>Journal of Urology</i> , 2011 , 185, 706-11	2.5	72
349	Decreased RECK and Increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness. <i>Pathobiology</i> , 2011 , 78, 123-31	3.6	12
348	Preanalytical interferences compromise the clinical validity of matrix metalloproteinase 1 as marker of colorectal cancer. <i>Annals of Surgical Oncology</i> , 2011 , 18 Suppl 3, S231-2; author reply S233-4	3.1	
347	The androgen-regulated Calcium-Activated Nucleotidase 1 (CANT1) is commonly overexpressed in prostate cancer and is tumor-biologically relevant in vitro. <i>American Journal of Pathology</i> , 2011 , 178, 1847-60	5.8	22
346	Metastamirs: a stepping stone towards improved cancer management. <i>Nature Reviews Clinical Oncology</i> , 2011 , 8, 75-84	19.4	158
345	Importance of brain-type fatty acid binding protein for cell-biological processes in human renal carcinoma cells. <i>Oncology Reports</i> , 2011 , 25, 1307-12	3.5	9
344	miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression. <i>International Journal of Oncology</i> , 2011 , 39, 1183-92	4.4	30
343	Metabolic profiling reveals key metabolic features of renal cell carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2011 , 15, 109-18	5.6	80
342	Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid. <i>European Urology</i> , 2011 , 59, 604-12	10.2	29
341	Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases. <i>Analytical Biochemistry</i> , 2011 , 417, 233-41	3.1	75
340	New 4-maleamic acid and 4-maleamide peptidyl chalcones as potential multitarget drugs for human prostate cancer. <i>Pharmaceutical Research</i> , 2011 , 28, 907-19	4.5	22
339	Fatty acid binding proteins (FABPs) in prostate, bladder and kidney cancer cell lines and the use of IL-FABP as survival predictor in patients with renal cell carcinoma. <i>BMC Cancer</i> , 2011 , 11, 302	4.8	41
338	Is there an optimal prostate-specific antigen threshold for prostate biopsy?. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 1215-21	3.5	4

337	Between-method differences in prostate-specific antigen assays affect prostate cancer risk prediction by nomograms. <i>Clinical Chemistry</i> , 2011 , 57, 995-1004	5.5	19
336	MicroRNAs as regulators of signal transduction in urological tumors. <i>Clinical Chemistry</i> , 2011 , 57, 954-68	5.5	97
335	Avoiding pitfalls in applying prediction models, as illustrated by the example of prostate cancer diagnosis. <i>Clinical Chemistry</i> , 2011 , 57, 1490-8	5.5	9
334	Assay-dependent abnormalities in measurements of prostate-specific antigen in serum: an occasional occurrence, but of clinical significance. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011 , 50, 585-6	5.9	2
333	Comparison of the diagnostic value of fatty acid synthase (FASN) with alpha-methylacyl-CoA racemase (AMACR) as prostatic cancer tissue marker. <i>Histopathology</i> , 2010 , 56, 811-5	7.3	19
332	Internal validation of an artificial neural network for prostate biopsy outcome. <i>International Journal of Urology</i> , 2010 , 17, 62-8	2.3	9
331	Methodological weakness in using correlation coefficients for assessing the interchangeability of analyte data between samples collected under different sampling conditions--the example of matrix metalloproteinase 9 determined in serum and plasma samples. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010 , 48, 733-6	5.9	5
330	Suitable reference genes for relative quantification of miRNA expression in prostate cancer. <i>Experimental and Molecular Medicine</i> , 2010 , 42, 749-58	12.8	89
329	Prostate cancer screening with prostate-specific antigen testing: more answers or more confusion?. <i>Clinical Chemistry</i> , 2010 , 56, 345-51	5.5	19
328	Gene promoter methylation and its potential relevance in early prostate cancer diagnosis. <i>Pathobiology</i> , 2010 , 77, 260-6	3.6	22
327	Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience. <i>Journal of Urology</i> , 2010 , 183, 126-31	2.5	51
326	Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature. <i>Clinica Chimica Acta</i> , 2010 , 411, 1611-24	6.2	255
325	MicroRNAs and cancer: current state and future perspectives in urologic oncology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010 , 28, 4-13	2.8	65
324	Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. <i>Nature Reviews Urology</i> , 2010 , 7, 286-97	5.5	88
323	Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. <i>Clinical Chemistry</i> , 2010 , 56, 998-1006	5.5	224
322	Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. <i>International Journal of Cancer</i> , 2010 , 126, 1166-76	7.5	464
321	Measurement conditions for flow cytometry analyses of cell lines from urological carcinomas. <i>Journal of Fluorescence</i> , 2010 , 20, 779-86	2.4	2
320	Periostin is up-regulated in high grade and high stage prostate cancer. <i>BMC Cancer</i> , 2010 , 10, 273	4.8	58

319	Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. <i>European Urology</i> , 2010 , 58, 12-8; discussion 20-1	10.2	175
318	Re: MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells. <i>European Urology</i> , 2010 , 57, 919	10.2	2
317	Reply to Arun Sreekumar, Laila M. Poisson, Thekkelnaycke M. Rajendiran, et al. Letter to the Editor re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in Urine after Digital Rectal Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours. <i>Eur Urol</i> 2010;58:12B. <i>European Urology</i> , 2010 , 58, e41-e42	10.2	4
316	Reply to Amitha K Hewavitharana Letter to the Editor re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in Urine After Digital Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours. <i>Eur Urol</i> 2010;58:12B. <i>European Urology</i> , 2010 , 58, e41-e42	10.2	2
315	KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy. <i>International Journal of Cancer</i> , 2010 , 127, 2386-94	7.5	11
314	Impact of RNA degradation on gene expression profiling. <i>BMC Medical Genomics</i> , 2010 , 3, 36	3.7	126
313	Diagnostic and prognostic value of T-cell receptor gamma alternative reading frame protein (TARP) expression in prostate cancer. <i>Histology and Histopathology</i> , 2010 , 25, 733-9	1.4	12
312	20-25% Lower Concentrations of Total and Free Prostate-Specific Antigen (PSA) after Calibration of PSA Assays to the WHO Reference Materials Analysis of 1098 Patients in Four Centers. <i>International Journal of Biological Markers</i> , 2009 , 24, 65-69	2.8	2
311	Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009 , 47, 1325-31	5.9	24
310	Germ cell tumors of the gonads: a selective review emphasizing problems in drug resistance and current therapy options. <i>Oncology</i> , 2009 , 76, 77-84	3.6	12
309	Reduced serum selenoprotein P concentrations in German prostate cancer patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 2386-90	4	23
308	Consideration of preanalytical impact of blood sampling on measurement of matrix metalloproteinases and their inhibitors as precondition to evaluate their relationship to clinical data. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 1372-3; author reply 1374-5	5	2
307	Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?. <i>BMC Cancer</i> , 2009 , 9, 248	4.8	17
306	Down-regulation of the pro-apoptotic XIAP associated factor-1 (XAF1) during progression of clear-cell renal cancer. <i>BMC Cancer</i> , 2009 , 9, 276	4.8	16
305	MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. <i>Journal of Cellular and Molecular Medicine</i> , 2009 , 13, 3918-28	5.6	194
304	Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. <i>European Urology</i> , 2009 , 55, 669-78	10.2	53
303	A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. <i>Prostate</i> , 2009 , 69, 198-207	4.2	77
302	Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid. <i>Prostate</i> , 2009 , 69, 624-32	4.2	38

301	By mistakes we learn: determination of matrix metalloproteinase-8 and tissue inhibitor of matrix metalloproteinase-1 in serum yields doubtful results. <i>Journal of Clinical Periodontology</i> , 2009 , 36, 34-5; author reply 36-8	7.7	2
300	Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. <i>European Journal of Cancer</i> , 2009 , 45, 478-89	7.5	81
299	Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network. <i>Urology</i> , 2009 , 74, 873-7	1.6	18
298	Synthesis of 7-chloroquinoliny-4-. <i>Scientia Pharmaceutica</i> , 2009 , 77,	4.3	27
297	Translating molecular medicine into clinical tools: doomed to fail by neglecting basic preanalytical principles. <i>Journal of Translational Medicine</i> , 2009 , 7, 87	8.5	11
296	20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials--analysis of 1098 patients in four centers. <i>International Journal of Biological Markers</i> , 2009 , 24, 65-9	2.8	19
295	New markers and multivariate models for prostate cancer detection. <i>Anticancer Research</i> , 2009 , 29, 2589-2600	2.9	18
294	Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. <i>British Journal of Cancer</i> , 2008 , 98, 604-10	8.7	378
293	Is serum matrix metalloproteinase 9 a useful biomarker in detection of colorectal cancer? Considering pre-analytical interference that may influence diagnostic accuracy. <i>British Journal of Cancer</i> , 2008 , 99, 553-4; author reply 555	8.7	10
292	GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. <i>British Journal of Cancer</i> , 2008 , 99, 939-48	8.7	105
291	An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics. <i>BJU International</i> , 2008 , 102, 799-805	5.6	25
290	Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas. <i>Cancer Science</i> , 2008 , 99, 1188-94	6.9	44
289	A strong note of caution in using matrix metalloproteinase-1 and its inhibitor, TIMP-1 in serum as biomarkers in systolic heart failure. <i>Journal of Internal Medicine</i> , 2008 , 264, 291-3	10.8	3
288	ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression. <i>BMC Cancer</i> , 2008 , 8, 179	4.8	54
287	Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. <i>BMC Cancer</i> , 2008 , 8, 381	4.8	124
286	Editorial comment on: diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of . <i>European Urology</i> , 2008 , 54, 369-70	10.2	
285	ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. <i>European Urology</i> , 2008 , 54, 1097-106	10.2	61
284	Words of wisdom. Re: the metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions. <i>European Urology</i> , 2008 , 54, 1198-9	10.2	2

283	Re: Application of artificial intelligence to the management of urological cancer. M. F. Abbod, J. W. Catto, D. A. Linkens and F. C. Hamdy J Urol 2007; 178: 1150-1156. <i>Journal of Urology</i> , 2008 , 179, 2067	2.5	1
282	Re: Al-Azab R, Toi A, Lockwood G, et al. Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL (Urology 69:103-107, 2007). <i>Urology</i> , 2008 , 72, 951	1.6	
281	Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma. <i>Cancer Letters</i> , 2008 , 269, 85-92	9.9	48
280	Blood sampling and the measurement of circulating matrix metalloproteinase-8. <i>Clinica Chimica Acta</i> , 2008 , 390, 156-7, author reply 158	6.2	3
279	Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. <i>Journal of Proteome Research</i> , 2008 , 7, 3329-38	5.6	127
278	Measurement of matrix metalloproteinases and their tissue inhibitors in serum produces doubtful results. <i>Journal of Infectious Diseases</i> , 2008 , 198, 1722-3; author reply 1723-4	7	4
277	Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008 , 46, 623-9	5.9	21
276	European and US publications in the 50 highest ranking pathology journals from 2000 to 2006. <i>Journal of Clinical Pathology</i> , 2008 , 61, 474-81	3.9	11
275	Claudin-1 protein expression is a prognostic marker of patient survival in renal cell carcinomas. <i>Clinical Cancer Research</i> , 2008 , 14, 7035-42	12.9	35
274	Matrix metalloproteinase-8 and tissue inhibitor of metalloproteinase-1 in serum do not reflect the analytes circulating in blood. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008 , 28, e15-6; author reply e17	9.4	17
273	CD146 protein in prostate cancer: revisited with two different antibodies. <i>Pathology</i> , 2008 , 40, 457-64	1.6	7
272	High expression of KLK14 in prostatic adenocarcinoma is associated with elevated risk of prostate-specific antigen relapse. <i>Tumor Biology</i> , 2008 , 29, 1-8	2.9	16
271	Impact of blood sampling on the circulating matrix metalloproteinases 1, 2, 3, 7, 8, and 9. <i>Clinical Chemistry</i> , 2008 , 54, 772-3	5.5	43
270	Tietz Fundamentals of Clinical Chemistry, 6th edition. Carl A. Burtis, Edward R. Ashwood, and David E. Bruns, editors. St Louis, MO: Saunders/Elsevier, 2008, 976 pp, \$96.95. ISBN 978-0-7216-3865-2.. <i>Clinical Chemistry</i> , 2008 , 54, 1933-1933	5.5	3
269	Matrix metalloproteinases do not properly work as peripheral blood biomarkers without taking into account the preanalytical impact of blood sampling. <i>European Journal of Cardio-thoracic Surgery</i> , 2008 , 33, 944; author reply 945	3	1
268	Circulating matrix metalloproteinase-7: an early or metastatic marker for renal cell carcinoma?. <i>Clinical Chemistry</i> , 2008 , 54, 1927-9	5.5	2
267	Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression 2008 ,		5
266	Artificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocity. <i>BMC Urology</i> , 2008 , 8, 10	2.2	5

265	GOLPH2 expression in renal cell cancer. <i>BMC Urology</i> , 2008 , 8, 15	2.2	31
264	Blood sampling affects circulating TIMP-1 concentration, a useful biomarker in estimating liver fibrosis stages. <i>Hepatology</i> , 2008 , 48, 688-9; author reply 689-90	11.2	5
263	Serum samples are inappropriate for use in measuring circulating matrix metalloproteinases: comment on the article by Young-Min et al. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1557-8; author reply 1559		1
262	Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood. <i>Clinical Biochemistry</i> , 2008 , 41, 1466-73	3.5	24
261	By mistakes we learn: determination of matrix metalloproteinase-8 and tissue inhibitor of matrix metalloproteinase-1 in serum yields doubtful results. <i>Journal of Clinical Periodontology</i> , 2008 , 35, 1087-8	7.7	4
260	Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. <i>Journal of Urology</i> , 2007 , 177, 1753-8	2.5	69
259	In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR. <i>BMC Molecular Biology</i> , 2007 , 8, 47	4.5	124
258	Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective phase I trial. <i>International Journal of Hyperthermia</i> , 2007 , 23, 315-23	3.7	269
257	Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of Polo-like kinase-1. <i>Prostate</i> , 2007 , 67, 361-9	4.2	22
256	Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. <i>Prostate</i> , 2007 , 67, 330-40	4.2	70
255	S100A8, S100A9, and the S100A8/A9 complex in circulating blood are not associated with prostate cancer risk-A re-evaluation study. <i>Prostate</i> , 2007 , 67, 1301-7	4.2	8
254	Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies. <i>BJU International</i> , 2007 , 99, 1427-31	5.6	25
253	Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy. <i>European Urology</i> , 2007 , 51, 1259-66	10.2	24
252	Re: Felix K.-H. Chun, Markus Graefen, Alberto Briganti, Andrea Gallina, Julia Hopp, Michael W. Kattan, Hartwig Huland and Pierre I. Karakiewicz. Initial biopsy outcome prediction--head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. <i>Eur Urol</i> 2007 ;51:1236-43. <i>European Urology</i> , 2007 , 51, 1446-7; author reply 1446	10.2	4
251	Re: A molecular correlate to the Gleason grading system for prostate adenocarcinoma. <i>European Urology</i> , 2007 , 51, 851-2	10.2	
250	Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression. <i>European Urology</i> , 2007 , 52, 1381-7	10.2	55
249	Reply to C.J. Shukla, Dylan Edwards and Krishna K. Sethia Letter to the Editor re: Anja Rabien, Mick Burkhardt, Monika Jung, Florian Fritzsche, Martin Ringsdorf, Hanka Schick Tanz, Stefan A. Loening, Glen Kristiansen and Klaus Jung. Decreased RECK Expression Indicating Proteolytic Imbalance in Prostate Cancer is Associated with Higher Tumor Aggressiveness and Risk of	10.2	
248	A bibliometric evaluation of publications in urological journals among European Union countries between 2000-2005. <i>European Urology</i> , 2007 , 52, 1238-48	10.2	45

247	Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2-10 ng/ml in 4,480 men. <i>World Journal of Urology</i> , 2007 , 25, 95-103	4	16
246	Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007 , 133, 643-52	4.9	48
245	Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. <i>Clinical Biochemistry</i> , 2007 , 40, 119-23	3.5	96
244	Free PSA forms in prostatic tissue and sera of prostate cancer patients: analysis by 2-DE and western blotting of immunopurified samples. <i>Clinical Biochemistry</i> , 2007 , 40, 343-50	3.5	28
243	Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model. <i>Cancer Chemotherapy and Pharmacology</i> , 2007 , 59, 275-82	3.5	2
242	Two-Dimensional Electrophoresis in Prostate Cancer Research and Diagnostics. <i>Laboratory Medicine</i> , 2007 , 38, 735-739	1.6	
241	Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics. <i>Urology</i> , 2007 , 69, 320-5	1.6	4
240	Comparison of two different artificial neural networks for prostate biopsy indication in two different patient populations. <i>Urology</i> , 2007 , 70, 596-601	1.6	17
239	PSA and other tissue kallikreins for prostate cancer detection. <i>European Journal of Cancer</i> , 2007 , 43, 1918-26	7.5	61
238	PSA and new biomarkers within multivariate models to improve early detection of prostate cancer. <i>Cancer Letters</i> , 2007 , 249, 18-29	9.9	48
237	A (-5, -7) proPSA based artificial neural network to detect prostate cancer. <i>European Urology</i> , 2006 , 50, 1014-20	10.2	31
236	Complications, urinary continence, and oncologic outcome of 1000 laparoscopic transperitoneal radical prostatectomies-experience at the Charité Hospital Berlin, Campus Mitte. <i>European Urology</i> , 2006 , 50, 1278-82; discussion 1283-4	10.2	72
235	Sample processing and its preanalytical impact on the measurement of circulating matrix metalloproteinases. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006 , 44, 500-2	5.9	5
234	Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network. <i>Biological Chemistry</i> , 2006 , 387, 801-5	4.5	14
233	Impact of blood sampling on circulating tissue inhibitors of metalloproteinases. <i>Clinical Cancer Research</i> , 2006 , 12, 2648; author reply 2648-9	12.9	2
232	Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, Fourth Edition. Carl A. Burtis, Edward R. Ashwood, and David E. Bruns, editors. St. Louis, MO: Elsevier Saunders, 2006, 2448 pp., \$229.00, hardcover. ISBN 0-7216-0189-8.. <i>Clinical Chemistry</i> , 2006 , 52, 1214-1214	5.5	5
231	Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status. <i>British Journal of Cancer</i> , 2006 , 94, 540-7	8.7	19
230	Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. <i>Clinical Cancer Research</i> , 2006 , 12, 89-96	12.9	98

229	Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. <i>Clinical Chemistry</i> , 2006 , 52, 59-64	5.5	108
228	Identification and validation of suitable endogenous reference genes for gene expression studies of human bladder cancer. <i>Journal of Urology</i> , 2006 , 175, 1915-20	2.5	94
227	Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma. <i>Journal of Urology</i> , 2006 , 176, 1326-31	2.5	29
226	New insights into the diagnostic accuracy of complexed and total prostate specific antigen using discordance analysis characteristics. <i>Journal of Urology</i> , 2006 , 175, 1275-80	2.5	8
225	Preanalytical pitfalls of blood sampling to measure true circulating matrix metalloproteinase 9 and tissue inhibitors of matrix metalloproteinases. <i>Clinica Chimica Acta</i> , 2006 , 373, 180-1; author reply 182	6.2	11
224	In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma. <i>Oncology Reports</i> , 2006 , 15, 1379	3.5	5
223	Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder. <i>BMC Urology</i> , 2006 , 6, 19	2.2	29
222	Thermotherapy using magnetic nanoparticles combined with external radiation in an orthotopic rat model of prostate cancer. <i>Prostate</i> , 2006 , 66, 97-104	4.2	98
221	Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. <i>Prostate</i> , 2006 , 66, 651-9	4.2	32
220	Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer. <i>International Journal of Urology</i> , 2006 , 13, 238-43	2.3	28
219	Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma. <i>Cell Death and Differentiation</i> , 2006 , 13, 619-27	12.7	87
218	ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006 , 449, 628-36	5.1	35
217	A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. <i>Journal of Urology</i> , 2005 , 174, 2150-3	2.5	34
216	Consideration of preanalytical conditions to use circulating matrix metalloproteinases as diagnostic markers. <i>Transplantation</i> , 2005 , 79, 744	1.8	3
215	Matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine: tumor-reducing effects on hormone-sensitive prostate cancer in rats. <i>Anti-Cancer Drugs</i> , 2005 , 16, 855-61	2.4	6
214	Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection. <i>BJU International</i> , 2005 , 96, 521-7	5.6	24
213	Re: Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA Level of 2-10 ng/ml: systematic review and meta-analysis. <i>Eur Urol</i> 2005;48:386-99. <i>European Urology</i> , 2005 , 48, 1059-60; author reply 1060-1	10.2	10
212	Serum or plasma: what kind of blood sample should be used to measure circulating matrix metalloproteinases and their inhibitors?. <i>Journal of Neuroimmunology</i> , 2005 , 162, 1-2	3.5	12

211	Misinterpretation of quantitative RT-PCR results: A comment on the article by Ohashi et al. "RNA degradation in human breast tissue after surgical removal: a time course study", <i>Exp. Mol. Pathol.</i> 77 (2004) 98-103. <i>Experimental and Molecular Pathology</i> , 2005 , 78, 263; author reply 264	4.4	1
210	Blood sampling as critical preanalytical determinant to use circulating MMP and TIMP as surrogate markers for pathological processes. <i>International Journal of Cancer</i> , 2005 , 116, 1000-1; author reply 1002-3	7.5	36
209	The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of Cancer, 2005 , 104, 993-1003	6.4	47
208	Careful attention to blood sampling as a preanalytical determinant of circulating matrix metalloproteinase 9 to avoid misinterpretations: comment on the article by Ainiala et al. <i>Arthritis and Rheumatism</i> , 2005 , 52, 673-4; author reply 674		4
207	Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization?. <i>Journal of Molecular Medicine</i> , 2005 , 83, 1014-24	5.5	177
206	Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation. <i>Prostate</i> , 2005 , 62, 34-9	4.2	6
205	Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy. <i>Prostate</i> , 2005 , 62, 224-32	4.2	31
204	Magnetic fluid hyperthermia (MFH) reduces prostate cancer growth in the orthotopic Dunning R3327 rat model. <i>Prostate</i> , 2005 , 64, 283-92	4.2	152
203	Pre-analytical conditions for the assessment of circulating MMP-9 and TIMP-1: consideration of pitfalls. <i>European Respiratory Journal</i> , 2005 , 26, 364-5; author reply 365-6	13.6	3
202	Consideration of important preanalytical conditions for the assessment of circulating matrix metalloproteinase-9. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005 , 172, 254; author reply 254	10.2	2
201	Discordance analysis characteristics as a new method to compare the diagnostic accuracy of tests: example of complexed versus total prostate-specific antigen. <i>Clinical Chemistry</i> , 2005 , 51, 532-9	5.5	9
200	Intron retention: a common splicing event within the human kallikrein gene family. <i>Clinical Chemistry</i> , 2005 , 51, 506-15	5.5	48
199	Artificial neural networks: has the time come for their use in prostate cancer patients?. <i>Nature Reviews Urology</i> , 2005 , 2, 262-3		8
198	In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder. <i>Oncology Reports</i> , 2004 , 12, 909	3.5	2
197	The kallikrein gene 5 splice variant 2 is a new biomarker for breast and ovarian cancer. <i>Tumor Biology</i> , 2004 , 25, 221-7	2.9	12
196	Analysis of subforms of free prostate-specific antigen in serum by two-dimensional gel electrophoresis: potential to improve diagnosis of prostate cancer. <i>Clinical Chemistry</i> , 2004 , 50, 2292-301	5.5	27
195	Serum macrophage migration inhibitory factor is not elevated in patients with prostate cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004 , 13, 328-9	4	2
194	Differential expression of a human kallikrein 5 (KLK5) splice variant in ovarian and prostate cancer. <i>Tumor Biology</i> , 2004 , 25, 149-56	2.9	18

193	Molecular cloning of a new gene which is differentially expressed in breast and prostate cancers. <i>Tumor Biology</i> , 2004 , 25, 122-33	2.9	11
192	Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy. <i>BJU International</i> , 2004 , 93, 1360-1	5.6	1
191	Re: Hessels D, Klein Gunnewiek JMT, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, Kiemeny LA, Witjes JA, Schalken JA. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. <i>Eur Urol</i> 2003;44:8-16. <i>European Urology</i> , 2004 , 46, 271-2	10.2	19
190	CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. <i>Prostate</i> , 2004 , 58, 183-92	4.2	109
189	Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. <i>Prostate</i> , 2004 , 60, 240-5	4.2	137
188	Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate-specific antigen levels Cancer, 2004 , 100, 1989-90; author reply 1989-90	6.4	1
187	Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. <i>International Journal of Cancer</i> , 2004 , 111, 783-91	7.5	170
186	Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. <i>Journal of Urology</i> , 2004 , 171, 187-91	2.5	105
185	The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers?. <i>Journal of Urology</i> , 2004 , 172, 2162-6	2.5	40
184	Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. <i>Cancer Letters</i> , 2004 , 205, 173-80	9.9	78
183	Expression of cathepsins B, H, and L and their inhibitors as markers of transitional cell carcinoma of the bladder. <i>Urology</i> , 2004 , 63, 1089-94	1.6	18
182	Evaluation of magnetic fluid hyperthermia in a standard rat model of prostate cancer. <i>Journal of Endourology</i> , 2004 , 18, 495-500	2.7	94
181	Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome. <i>Oncology Reports</i> , 2004 , 11, 529-36	3.5	37
180	Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. <i>British Journal of Cancer</i> , 2003 , 88, 1101-4	8.7	78
179	Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma. <i>Urological Research</i> , 2003 , 31, 358-62		12
178	Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats. <i>Prostate</i> , 2003 , 54, 206-11	4.2	12
177	mRNA expression of the five membrane-type matrix metalloproteinases MT1-MT5 in human prostatic cell lines and their down-regulation in human malignant prostatic tissue. <i>Prostate</i> , 2003 , 55, 89-98	4.2	21
176	Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. <i>Prostate</i> , 2003 , 56, 287-92	4.2	55

175	Quantitative Analysis of Kallikrein 15 Gene Expression in Prostate Tissue. <i>Journal of Urology</i> , 2003 , 169, 361-364	2.5	47
174	A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. <i>Journal of Urology</i> , 2003 , 170, 1175-9	2.5	31
173	Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues. <i>Urology</i> , 2003 , 61, 1042-6	1.6	37
172	Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. <i>Journal of Urology</i> , 2003 , 170, 2302-5	2.5	39
171	Changes in concentration of DNA in serum and plasma during storage of blood samples. <i>Clinical Chemistry</i> , 2003 , 49, 1028-9	5.5	174
170	Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy. <i>Clinical Chemistry</i> , 2003 , 49, 887-94	5.5	14
169	Comparison of eight computer programs for receiver-operating characteristic analysis. <i>Clinical Chemistry</i> , 2003 , 49, 433-9	5.5	112
168	Quantitative Analysis of Kallikrein 15 Gene Expression in Prostate Tissue. <i>Journal of Urology</i> , 2003 , 361-364		1
167	mRNA expression profile of matrix metalloproteinases and their tissue inhibitors in malignant and non-malignant prostatic tissue. <i>Anticancer Research</i> , 2003 , 23, 2617-24	2.3	12
166	The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. <i>Cancer Research</i> , 2003 , 63, 6543-6	10.1	38
165	Quantitative analysis of kallikrein 15 gene expression in prostate tissue. <i>Journal of Urology</i> , 2003 , 169, 361-4	2.5	11
164	Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. <i>European Urology</i> , 2002 , 42, 398-406	10.2	104
163	An artificial neural network considerably improves the diagnostic power of percent free prostate-specific antigen in prostate cancer diagnosis: results of a 5-year investigation. <i>International Journal of Cancer</i> , 2002 , 99, 466-73	7.5	40
162	Tissue inhibitors of metalloproteinases 1 and 2 in human seminal plasma and their association with spermatozoa. <i>Journal of Developmental and Physical Disabilities</i> , 2002 , 25, 369-71		11
161	Differential expression of matrix metalloproteinases and their tissue inhibitors in human primary cultured prostatic cells and malignant prostate cell lines. <i>Prostate</i> , 2002 , 50, 38-45	4.2	23
160	Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. <i>Prostate</i> , 2002 , 51, 126-32	4.2	57
159	Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers. <i>Prostate</i> , 2002 , 51, 35-41	4.2	35
158	The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. <i>Oncogene</i> , 2002 , 21, 2089-96	9.2	58

157	The novel synthetic inhibitor of matrix metalloproteinases Ro 28-2653 induces apoptosis in Dunning tumor cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2002 , 7, 217-20	5.4	6
156	Quantitative differences in matrix metalloproteinase (MMP)-2, but not in MMP-9, tissue inhibitor of metalloproteinase (TIMP)-1 or TIMP-2, in seminal plasma of normozoospermic and azoospermic patients. <i>Human Reproduction</i> , 2002 , 17, 2919-23	5.7	33
155	Increased production of matrix metalloproteinase-2 in alveolar macrophages and regulation by interleukin-10 in patients with acute pulmonary sarcoidosis. <i>Experimental Lung Research</i> , 2002 , 28, 55-68 ^{2.3}	2.3	22
154	RE: A PROSPECTIVE STUDY TO EVALUATE THE ROLE OF COMPLEXED PROSTATE SPECIFIC ANTIGEN AND FREE/TOTAL PROSTATE SPECIFIC ANTIGEN RATIO FOR THE DIAGNOSIS OF PROSTATE CANCER. <i>Journal of Urology</i> , 2002 , 167, 259-260	2.5	3
153	Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. <i>Urology</i> , 2002 , 59, 2-8	1.6	61
152	Cathepsins B, H, and L activities in urine of patients with transitional cell carcinoma of the bladder. <i>Urology</i> , 2002 , 59, 308-12	1.6	17
151	Differential expression of Kallikrein gene 5 in cancerous and normal testicular tissues. <i>Urology</i> , 2002 , 60, 714-8	1.6	41
150	Re: Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer (Respir Med 2001; 95: 1-4). <i>Respiratory Medicine</i> , 2002 , 96, 126-9	4.6	1
149	Circulating gelatinase B (MMP-9)--the impact of the preanalytical step of blood collection. <i>Matrix Biology</i> , 2002 , 21, 381-2	11.4	14
148	Prostate Cancer Screening. Ian M. Thompson, Martin I. Resnick, and Eric A. Klein, eds. Totowa, NJ: Humana Press, 2001, 317 pp. (plus one compact disc), \$99.50, hardcover. ISBN 0-89603-901-3.. <i>Clinical Chemistry</i> , 2002 , 48, 1817-1817	5.5	
147	Multicenter Evaluation of an Artificial Neural Network to Increase the Prostate Cancer Detection Rate and Reduce Unnecessary Biopsies. <i>Clinical Chemistry</i> , 2002 , 48, 1279-1287	5.5	113
146	Trace Protein, Cystatin C, α -Microglobulin, and Creatinine Compared for Detecting Impaired Glomerular Filtration Rates in Children. <i>Clinical Chemistry</i> , 2002 , 48, 729-736	5.5	177
145	Detection of Human Kallikrein 4 in Healthy and Cancerous Prostatic Tissues by Immunofluorometry and Immunohistochemistry. <i>Clinical Chemistry</i> , 2002 , 48, 1232-1240	5.5	60
144	Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. <i>Clinical Chemistry</i> , 2002 , 48, 1279-87	5.5	33
143	Tumor M2 pyruvate kinase in plasma of patients with urological tumors. <i>Tumor Biology</i> , 2001 , 22, 282-5	2.9	26
142	A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis. <i>Prostate</i> , 2001 , 47, 77-84	4.2	9
141	Receiver-operating characteristic as a tool for evaluating the diagnostic performance of prostate-specific antigen and its molecular forms--What has to be considered?. <i>Prostate</i> , 2001 , 46, 307-10 ^{1.2}	1.2	14
140	Dimethyl sulfoxide as additive in ready-to-use reaction mixtures for real-time polymerase chain reaction analysis with SYBR Green I dye. <i>Analytical Biochemistry</i> , 2001 , 289, 292-5	3.1	25

139	Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen . <i>International Journal of Cancer</i> , 2001 , 93, 759-65	7.5	24
138	Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue. <i>British Journal of Cancer</i> , 2001 , 85, 220-4	8.7	61
137	Expression and regulation of prostate androgen regulated transcript-1 (PART-1) and identification of differential expression in prostatic cancer. <i>British Journal of Cancer</i> , 2001 , 85, 393-7	8.7	23
136	Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer. <i>Journal of Biological Chemistry</i> , 2001 , 276, 53-61	5.4	89
135	Identification and characterization of a novel human testis-specific kinase substrate gene which is downregulated in testicular tumors. <i>Biochemical and Biophysical Research Communications</i> , 2001 , 285, 400-8	3.4	13
134	Molecular cloning of a novel human acid phosphatase gene (ACPT) that is highly expressed in the testis. <i>Genomics</i> , 2001 , 74, 385-95	4.3	47
133	Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. <i>Clinica Chimica Acta</i> , 2001 , 314, 241-4	6.2	96
132	Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. <i>Urology</i> , 2001 , 57, 675-9	1.6	74
131	Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis. <i>European Urology</i> , 2001 , 39, 57-64	10.2	13
130	Osteoprotegerin in Serum as a Novel Marker of Bone Metastatic Spread in Prostate Cancer. <i>Clinical Chemistry</i> , 2001 , 47, 2061-2063	5.5	40
129	ET-1 Protein Is Not Better than Cystatin C as an Indicator of Reduced Glomerular Filtration Rate. <i>Clinical Chemistry</i> , 2001 , 47, 2181-2181	5.5	34
128	Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma. <i>International Journal of Cancer</i> , 2000 , 85, 801-4	7.5	44
127	Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model. <i>Prostate</i> , 2000 , 43, 77-82	4.2	20
126	Ratio of Free or Complexed Prostate-specific Antigen (PSA) to Total PSA: Which Ratio Improves Differentiation between Benign Prostatic Hyperplasia and Prostate Cancer?. <i>Clinical Chemistry</i> , 2000 , 46, 55-62	5.5	78
125	Molecular Forms of Prostate-specific Antigen in Malignant and Benign Prostatic Tissue: Biochemical and Diagnostic Implications. <i>Clinical Chemistry</i> , 2000 , 46, 47-54	5.5	49
124	Elimination of serum complexed prostate-specific antigen after radical retropubic prostatectomy. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000 , 38, 309-11	5.9	1
123	Different stability of free and complexed prostate-specific antigen in serum in relation to specimen handling and storage conditions. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000 , 38, 1271-5	5.9	16
122	Relationship between semen quality and the seminal plasma components carnitine, alpha-glucosidase, fructose, citrate and granulocyte elastase in infertile men compared with a normal population. <i>Human Reproduction</i> , 2000 , 15, 840-5	5.7	70

121	Urinary markers of malignancy. <i>Clinica Chimica Acta</i> , 2000 , 297, 191-205	6.2	15
120	Laser-induced hyperthermia in rat prostate cancer: role of site of tumor implantation. <i>Urology</i> , 2000 , 56, 167-72	1.6	11
119	Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. <i>Urology</i> , 2000 , 56, 527-32	1.6	89
118	ACT-PSA and complexed PSA elimination kinetics in serum after radical retropubic prostatectomy: proof of new complex forming of PSA after release into circulation. <i>Urology</i> , 2000 , 55, 560-3	1.6	12
117	RE: COMPLEXED PROSTATE SPECIFIC ANTIGEN PROVIDES SIGNIFICANT ENHANCEMENT OF SPECIFICITY COMPARED WITH TOTAL PROSTATE SPECIFIC ANTIGEN FOR DETECTING PROSTATE CANCER. <i>Journal of Urology</i> , 2000 , 164, 1671-1671	2.5	7
116	Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model 2000 , 43, 77		1
115	Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications. <i>Clinical Chemistry</i> , 2000 , 46, 47-54	5.5	18
114	Metabolic rates of 4-hydroxynonenal in tubular and mesangial cells of the kidney. <i>Nephron Experimental Nephrology</i> , 1999 , 7, 59-62		4
113	A Gap Between Total Prostate-specific Antigen and the Sum of Free Prostate-specific Antigen Plus α -Antichymotrypsin-Prostate-specific Antigen in Patients with Prostate Carcinoma but not in Those with Benign Prostate Hyperplasia. <i>Clinical Chemistry</i> , 1999 , 45, 422-424	5.5	17
112	β Trace Protein in Serum: A New Marker of Glomerular Filtration Rate in the Creatinine-Blind Range. <i>Clinical Chemistry</i> , 1999 , 45, 567-568	5.5	106
111	Analytical aspects regarding the measurement of metalloproteinases. <i>Annals of the New York Academy of Sciences</i> , 1999 , 878, 491-3	6.5	2
110	Metalloproteinases and tissue inhibitors of matrix-metalloproteinases in plasma of patients with prostate cancer and in prostate cancer tissue. <i>Annals of the New York Academy of Sciences</i> , 1999 , 878, 544-6	6.5	9
109	Diagnostic sensitivity of serum cystatin for impaired glomerular filtration rate. <i>Pediatric Nephrology</i> , 1999 , 13, 501-5	3.2	77
108	Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue. <i>European Journal of Cancer</i> , 1999 , 35, 138-44	7.5	76
107	Different effects of cyclosporine and tacrolimus on the activation of mesangial metalloproteinases and their inhibitors. <i>Transplantation Proceedings</i> , 1999 , 31, 2757-8	1.1	1
106	Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA. <i>Urology</i> , 1999 , 53, 1160-7; discussion 1167-8	1.6	28
105	Re: Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples. <i>Journal of Urology</i> , 1999 , 162, 502-3	2.5	
104	Rapid detection of elevated prostate-specific antigen levels in blood: performance of various membrane strip tests compared. <i>Urology</i> , 1999 , 53, 155-60	1.6	22

103	Matrix metalloproteinases, but not cathepsins B, H, and L or their inhibitors in peripheral blood of patients with rheumatoid arthritis are potentially useful markers of disease activity. <i>Zeitschrift Fur Rheumatologie</i> , 1998 , 57, 392-8	1.9	22
102	Matrix metalloproteinase-2 in blood does not indicate the progression of prostate cancer. <i>International Journal of Cancer</i> , 1998 , 78, 392-3	7.5	7
101	Quantification of matrix metalloproteinases and tissue inhibitors of metalloproteinase in prostatic tissue: analytical aspects. <i>Prostate</i> , 1998 , 34, 130-6	4.2	25
100	Cathepsins B, H, L and cysteine proteinase inhibitors in renal cell carcinoma: no evidence for dysregulated proteolytic balance. <i>Journal of Cancer Research and Clinical Oncology</i> , 1998 , 124, 60-1	4.9	1
99	Periodate-oxidized ATP stimulates the permeability transition of rat liver mitochondria. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 1998 , 1363, 209-16	4.6	1
98	Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate. <i>Journal of Urology</i> , 1998 , 159, 1595-8	2.5	61
97	Relation of free PSA/total PSA in serum for differentiating between patients with prostatic cancer and benign hyperplasia of the prostate: which cutoff should be used?. <i>Cancer Investigation</i> , 1998 , 16, 45-9	2.1	11
96	Kind of Sample as Preanalytical Determinant of Matrix Metalloproteinases 2 and 9 and Tissue Inhibitor of Metalloproteinase 2 in Blood. <i>Clinical Chemistry</i> , 1998 , 44, 1060-1062	5.5	88
95	Preanalytical Determinants of Total and Free Prostate-Specific Antigen and Their Ratio: Blood Collection and Storage Conditions. <i>Clinical Chemistry</i> , 1998 , 44, 685-688	5.5	20
94	Elimination of serum free and total prostate-specific antigen after radical retropubic prostatectomy. <i>Clinical Chemistry and Laboratory Medicine</i> , 1997 , 35, 591-5	5.9	1
93	Präanalytische und analytische Aspekte bei der Bestimmung von Metalloproteinasen und ihren Inhibitoren im Blut. <i>Laboratoriums Medizin</i> , 1997 , 21, 207-213		
92	Das Verhältnis freies PSA/Gesamt-PSA - eine Kenngröße zur Differenzierung zwischen Patienten mit Prostatakarzinom und benigner Prostatahyperplasie: Welcher Diskriminationspunkt sollte gewählt werden?. <i>Aktuelle Urologie</i> , 1997 , 28, 323-328	0.4	1
91	Soluble CD44 variants in the serum of patients with urological malignancies. <i>Oncology</i> , 1997 , 54, 226-30	3.6	10
90	Re: Editorial: can prostate specific antigen derivatives reduce the frequency of unnecessary prostate biopsies?. <i>Journal of Urology</i> , 1997 , 157, 1371	2.5	11
89	Betaine improves the PCR amplification of GC-rich DNA sequences. <i>Nucleic Acids Research</i> , 1997 , 25, 3951-8	3.1	398
88	Effect of Starvation on Antioxidant Enzymes and Respiratory Mitochondrial Functions in Kidney and Liver from Rats.. <i>Journal of Clinical Biochemistry and Nutrition</i> , 1997 , 22, 163-169	3.1	3
87	Plasma but not serum should be used for determining tissue inhibitor of metalloproteinase in blood. <i>Alcoholism: Clinical and Experimental Research</i> , 1997 , 21, 1155-6	3.7	1
86	Antioxidant enzymes in malignant prostate cell lines and in primary cultured prostatic cells. <i>Free Radical Biology and Medicine</i> , 1997 , 23, 127-33	7.8	58

85	Differential response of oxygen radical metabolism in rat heart, liver and kidney to cyclosporine A treatment. <i>Inflammation Research</i> , 1997 , 46, 452-4	7.2	22
84	The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia 1997 , 79, 104-109		65
83	Increased analytical sensitivity of RT-PCR of PSA mRNA decreases diagnostic specificity of detection of prostatic cells in blood. <i>International Journal of Cancer</i> , 1997 , 70, 52-6	7.5	47
82	Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer. <i>International Journal of Cancer</i> , 1997 , 74, 220-3	7.5	52
81	Factors influencing the ratio of free to total prostate-specific antigen in serum. <i>International Journal of Cancer</i> , 1997 , 74, 630-6	7.5	53
80	Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood. <i>Clinical Biochemistry</i> , 1997 , 30, 491-6	3.5	54
79	The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia 1997 , 79, 104		3
78	Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia. <i>European Journal of Cancer</i> , 1996 , 32A, 627-30	7.5	10
77	What kind of specimen should be selected for determining tissue inhibitor of metalloproteinase-1 (TIMP-1) in blood?. <i>Clinica Chimica Acta</i> , 1996 , 254, 97-100	6.2	14
76	Comparison between equimolar- and skewed-response assays of prostate specific antigen: is there an influence on the clinical significance when measuring total serum prostate specific antigen?. <i>Annals of Clinical Biochemistry</i> , 1996 , 33 (Pt 3), 209-14	2.2	7
75	Developmental changes of antioxidant enzymes in kidney and liver from rats. <i>Free Radical Biology and Medicine</i> , 1996 , 20, 613-7	7.8	47
74	Non-hyperbolic calcium calibration curve of Fura-2: implications for the reliability of quantitative Ca ²⁺ measurements. <i>Cell Calcium</i> , 1996 , 20, 287-92	4	16
73	Isoforms of prostate-specific antigen in serum: a result of the glycosylation process in dysplastic prostatic cells?. <i>Prostate</i> , 1996 , 29, 65-6	4.2	2
72	Soluble CD44 variants in serum of patients with prostate cancer and other urological malignancies. <i>Prostate</i> , 1996 , 29, 334-5	4.2	2
71	Polymerase chain reaction in the detection of micrometastases and circulating tumor cells 1996 , 78, 2445-2447		4
70	The ratio of free to total prostate-specific antigen in serum is correlated to the prostate volume. <i>International Journal of Cancer</i> , 1996 , 67, 461-2	7.5	2
69	Rapid screening of PSA: evaluation of an immunochemical membrane strip test. <i>Clinical Chemistry</i> , 1995 , 41, 1545-1547	5.5	5
68	Cystatin C: a promising marker of glomerular filtration rate to replace creatinine. <i>Nephron</i> , 1995 , 70, 370-1	3.3	45

67	Lower serum high-density lipoprotein-cholesterol concentration in patients undergoing maintenance hemodialysis with acetate than with bicarbonate. <i>American Journal of Kidney Diseases</i> , 1995 , 25, 584-8	7.4	10
66	Culture of Human Kidney Proximal Tubular Cells – The Effect of Various Detachment Procedures on Viability and Degree of Cell Detachment. <i>Cellular Physiology and Biochemistry</i> , 1995 , 5, 353-360	3.9	15
65	Changed excretion of urinary proteins and enzymes by chronic exposure to lead. <i>Nephrology Dialysis Transplantation</i> , 1994 , 9, 613-8	4.3	27
64	Niedermolekulare Proteine im Serum als Marker der glomerulären Filtrationsrate: Cystatin C, β_2 -Mikroglobulin und α_2 -Mikroglobulin. <i>Laboratoriums Medizin</i> , 1994 , 18, 461-465		1
63	Excretion of urinary enzymes after extracorporeal shock wave lithotripsy: a critical reevaluation. <i>Journal of Urology</i> , 1993 , 149, 1409-13	2.5	27
62	What are the criteria to introduce new methods for determination of urinary N-acetyl-beta-D-glucosaminidase activity?. <i>Annals of Clinical Biochemistry</i> , 1993 , 30 (Pt 5), 501-4	2.2	3
61	Effect of storage temperature on the activity of superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase and glutathione S-transferase in rat liver and kidney homogenates. <i>Enzyme & Protein</i> , 1993 , 47, 149-55		10
60	Renal fibronectin excretion as a marker for renal environmental toxins. <i>Contributions To Nephrology</i> , 1993 , 101, 177-84	1.6	1
59	Sandwich enzyme immunoassay of cystatin C in serum with commercially available antibodies. <i>Clinical Chemistry</i> , 1993 , 39, 1885-1890	5.5	86
58	Comparison of the effects of the immunosuppressive agents FK 506 and cyclosporin A on rat kidney mitochondria. <i>Biochemical Pharmacology</i> , 1993 , 46, 829-32	6	37
57	Cyclosporine A inhibits ATP net uptake of rat kidney mitochondria. <i>Biochemical Pharmacology</i> , 1992 , 43, 1021-4	6	18
56	Reference intervals for alpha 1-microglobulin in urine. <i>Clinica Chimica Acta</i> , 1992 , 206, 245-7	6.2	13
55	Sex- and age-dependent reference values of alpha-1-microglobulin in urine. <i>Nephron</i> , 1992 , 62, 474-5	3.3	7
54	Ein kontinuierlicher Test zur Bestimmung der N-Acetyl- β -D-glucosaminidase-Aktivität im Harn mit dem Substrat 3,3'-Dichlorphenol-sulfonphthaleinyl-N-acetyl- β -D-glucosaminid: ein Vergleich mit anderen Methoden ohne Probenvorbereitung. <i>Laboratoriums Medizin</i> , 1991 , 15, 429-431		
53	Ischemia decreases the content of the adenine nucleotide translocator in mitochondria of rat kidney. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 1991 , 1056, 71-5	4.6	21
52	A practical new assay for determining N-acetyl-beta-D-glucosaminidase activity in urine. <i>Clinica Chimica Acta</i> , 1991 , 203, 405-7	6.2	2
51	Methods compared for determining activity of N-acetyl-beta-D-glucosaminidase in urine without pretreatment of sample: different sensitivity and species effect. <i>Enzyme</i> , 1991 , 45, 215-21		8
50	Single-injection inulin clearance using only one blood sample as a suitable procedure to measure glomerular filtration rate. <i>Nephron</i> , 1991 , 59, 694-5	3.3	3

49	Mechanisms accounting for changes of adenine nucleotide content in mitochondria at ischemia. <i>Advances in Experimental Medicine and Biology</i> , 1991 , 309A, 309-12	3.6	1
48	Influence of preservation solutions on lipid peroxidation and mitochondrial respiration in rat kidneys. <i>Transplantation</i> , 1990 , 49, 890-4	1.8	2
47	Ischemia-induced alterations of rat kidney mitochondria. <i>Transplantation</i> , 1990 , 49, 997-9	1.8	1
46	Determination of purine compounds by ion-pair microbore high-performance liquid chromatography: application to ischemic rat kidney mitochondria. <i>Biomedical Applications</i> , 1990 , 527, 498-501		4
45	How should we measure activity of alanine aminopeptidase in urine?. <i>Clinical Chemistry</i> , 1990 , 36, 177-178	3.5	1
44	Refinements of assays for low concentrations of inulin in serum. <i>Nephron</i> , 1990 , 54, 360-1	3.3	33
43	Age-dependent excretion of alanine aminopeptidase, alkaline phosphatase, gamma-glutamyltransferase and N-acetyl-beta-D-glucosaminidase in human urine. <i>Enzyme</i> , 1990 , 43, 10-6		26
42	A microalbuminuria assay using bromphenol blue. <i>Clinica Chimica Acta</i> , 1990 , 187, 163-72	6.2	14
41	Measurement of lysozyme in human body fluids: comparison of various enzyme immunoassay techniques and their diagnostic application. <i>Clinical Biochemistry</i> , 1989 , 22, 349-55	3.5	116
40	Further evidence for tubular dysfunction in insulin dependent diabetes. <i>The Journal of Diabetic Complications</i> , 1989 , 3, 167-71		6
39	Adenosine formation by isolated rat kidney mitochondria. <i>FEBS Letters</i> , 1989 , 254, 5-7	3.8	7
38	Quality control material for activity determinations of urinary enzymes. <i>Clinical Biochemistry</i> , 1988 , 21, 53-7	3.5	8
37	Class II antigen expression by keratinocytes and enterocytes--an early feature of graft-versus-host-disease. <i>Transplantation</i> , 1988 , 46, 402-6	1.8	32
36	Diagnostic significance of different urinary enzymes in patients suffering from chronic renal diseases. <i>Clinica Chimica Acta</i> , 1987 , 168, 287-95	6.2	39
35	31P-NMR spectroscopy and ultrastructural studies on nephrotoxicity of cyclosporine A. <i>Experimental Pathology</i> , 1987 , 32, 73-9		1
34	Low-molecular-mass proteins in serum and their relationship to the glomerular filtration rate. <i>Nephron</i> , 1987 , 47, 160		11
33	Inhibited efficiency of kidney mitochondria isolated from rats treated with cyclosporin A. <i>Nephron</i> , 1987 , 45, 43-5	3.3	26
32	An optimized micromethod for determining the catalytic activity of serum ribonuclease. <i>Clinical Chemistry and Laboratory Medicine</i> , 1986 , 24, 243-50	5.9	

31	Diuresis-dependent excretion of multiple forms of renal brush-border enzymes in urine. <i>Clinica Chimica Acta</i> , 1986 , 156, 77-83	6.2	14
30	Diagnostic significance of urinary enzymes in detecting acute rejection crises in renal transplant recipients depending on expression of results illustrated through the example of alanine aminopeptidase. <i>Clinical Biochemistry</i> , 1985 , 18, 257-60	3.5	14
29	Influence of cyclosporin A on the respiration of isolated rat kidney mitochondria. <i>FEBS Letters</i> , 1985 , 183, 167-9	3.8	80
28	Changed enzyme activities in rat kidney during ischemia. <i>Journal of Surgical Research</i> , 1985 , 39, 454-60	2.5	1
27	Phosphatidic acid phosphatase activity in subcellular fractions of normal and dystrophic human muscle. <i>Clinica Chimica Acta</i> , 1985 , 146, 167-74	6.2	2
26	Long-term stability of enzymes in human serum stored in liquid nitrogen. <i>Enzyme</i> , 1984 , 31, 209-16		10
25	Increased serum gamma-glutamyltransferase activity in renal transplant recipients: liver damage or microsomal enzyme induction?. <i>Clinica Chimica Acta</i> , 1984 , 141, 1-5	6.2	1
24	Stability of enzymes in urine at 37 degrees C. <i>Clinica Chimica Acta</i> , 1983 , 131, 185-91	6.2	23
23	Lecithin:cholesterol acyltransferase activity and HDL composition in serum of patients with kidney transplants. <i>Enzyme</i> , 1983 , 29, 54-7		
22	Suitability of commercial control sera of the quality control of activity determination of gamma-glutamyl transferase. <i>Clinica Chimica Acta</i> , 1982 , 120, 367-71	6.2	
21	On the pyridoxal-5'-phosphate stimulation of aspartate aminotransferase and alanine aminotransferase in serum and erythrocytes of patients undergoing chronic haemodialysis and with kidney transplants. <i>Clinica Chimica Acta</i> , 1981 , 115, 105-10	6.2	19
20	Increased creatine kinase BB activity in rat plasma induced by hypoxia. <i>Enzyme</i> , 1980 , 25, 60-3		4
19	Lecithin: cholesterol acyltransferase activity, HDL-cholesterol and apolipoprotein A in serum of patients undergoing chronic haemodialysis. <i>Enzyme</i> , 1980 , 25, 273-5		20
18	Influence of inorganic phosphate on the activity determination of isoenzymes of alkaline phosphatase in various buffer systems. <i>Clinica Chimica Acta</i> , 1980 , 102, 215-9	6.2	11
17	On the influence of reaction conditions in activity determination of alkaline phosphatase on the molar absorptivity of 4-nitrophenol. <i>Clinica Chimica Acta</i> , 1980 , 101, 1-4	6.2	1
16	Suitability of commercial control sera for the quality control of activity determination of alkaline phosphatase. <i>Clinica Chimica Acta</i> , 1979 , 97, 171-8	6.2	3
15	Creatine kinase isoenzyme BB in serum of healthy adults and children. <i>Clinica Chimica Acta</i> , 1979 , 91, 165-8	6.2	19
14	Stability of isoenzymes of alkaline phosphatase in various buffer systems. <i>Enzyme</i> , 1979 , 24, 18-22		4

13	Creatine kinase isoenzyme BB in serum of patients undergoing chronic hemodialysis and with kidney transplant. <i>Enzyme</i> , 1979 , 24, 169-72		5
12	Influence of Mg ²⁺ ions on the activity measurement of isoenzymes of alkaline phosphatase. <i>Enzyme</i> , 1979 , 24, 322-6		2
11	The apoenzyme of aspartate aminotransferase and alanine aminotransferase in the serum of healthy persons and patients suffering from liver diseases. <i>Clinica Chimica Acta</i> , 1978 , 90, 143-9	6.2	8
10	Lecithin: cholesterol acyltransferase activity in patients with chronic liver diseases and positive LP-X tests. <i>Digestion</i> , 1978 , 17, 445-8	3.6	
9	Relative stimulation of aspartate aminotransferase activity in human serum by pyridoxal 5'-phosphate in myocardial infarction. <i>Enzyme</i> , 1978 , 23, 201-5		3
8	Exchange of different phosphatidylcholine molecular species by phospholipid exchange protein of rat liver. <i>FEBS Letters</i> , 1977 , 74, 220-4	3.8	10
7	Comparative determinations of aminotransferase activities in serum with so-called "optimised" methods. <i>Clinica Chimica Acta</i> , 1977 , 81, 299-304	6.2	8
6	Suitability of commercial enzyme control sera for the quality control of activity determinations of L-aspartate aminotransferase and L-alanine aminotransferase in human serum. <i>Clinica Chimica Acta</i> , 1977 , 79, 515-26	6.2	9
5	Effect of pyridoxal 5'-phosphate on the temperature relationships of alanine aminotransferase. <i>Clinica Chimica Acta</i> , 1975 , 64, 329-31	6.2	3
4	An Optimized Assay of Human Serum Glutamate Dehydrogenase Activity. <i>Enzyme</i> , 1972 , 14, 44-54		8
3	Diuresis-dependent excretions of low-molecular mass proteins in urine: β -microglobulin, lysozyme, and ribonuclease		1
2	Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome. <i>Oncology Reports</i> ,	3.5	5
1	Metabolic reprogramming and elevation of glutathione in chromophobe renal cell carcinomas		4